Broad Survival Benefit from MATTERHORN Trial
The MATTERHORN trial's results show a new approach to biomarker use, potentially expanding access to immunotherapy in early gastric and GEJ cancer treatment.
Nancy Ghattas, VP, US Oncology Commercial Franchise Head of Immuno-Oncology at AstraZeneca, discussed the trial's significance in a video interview.
The Imfinzi-based perioperative regimen demonstrated a 22% reduction in the risk of death and improved overall survival regardless of PD-L1 status.
This marks the first immunotherapy in this setting to show such benefit, reshaping biomarker strategies.
Author's summary: MATTERHORN trial expands immunotherapy access.
More News
- Nexchain (NEX) Presale Moves to New Phase as XRP Finds Major Support
- Anti-ransomware fighter Halcyon signs North American distribution deal with Climb Channel Solutions
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- Leftist virtue signalling is getting us nowhere
- Amazon layoffs: What they signal for HR leaders
- Best early Black Friday deals 2025: 40+ sales out early
- Sen. Addabbo hears constituents’ concerns at Deja Brew in Richmond Hill – QNS
- Eala falls to Mboko to exit Hong Kong Open
- 'No is a full sentence.' Advice on HR priorities from world-class CHROs
- Mono Protocol’s $MONO token presale attracts attention across global crypto communities - CoinJournal